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Background. The purpose of this study was to analyze the secular trends of infective endocarditis in a teaching hospital between 
January 1996 and December 2015.
Methods. We report on a single-center retrospective study of patients with left-side valve infective endocarditis. We performed 
an analysis of secular trends in the main epidemiological and etiological aspects, as well as clinical outcomes, in 5 successive 4-year 
periods (P1 to P5).
Results. In total, 595 episodes of infective endocarditis were included, of which 76% were community-acquired and 31.3% 
involved prosthetic valves. Among the cases, 70% occurred in men, and the mean age (SD) was 64.1  (14.3) years. A significant 
increase in older patients (age ≥70 years) between P1 (15.332%) and P5 (51.9%; P < .001) was observed. The rate of infective endo-
carditis on biological prostheses also increased in the prosthetic group, accounting for 30% in P1 and 67.3% in P5 (P < .001). By 
contrast, there were significant decreases in vascular and immunological phenomena over the study period, with decreases in the 
presence of moderate to severe valvular insufficiency (75.9% in P1 to 52.6% in P5; P < .001) and valvular surgery (43% in P1 vs 29.6% 
in P5; P = .006). Finally, overall mortality was 23.9%, and although it was highest in P1, it subsequently remained stable through P2 
to P5 (38% in P1 to 20% in P5; P = .004).
Conclusions. There has been a significant increase in infective endocarditis in older patients. The decrease in moderate to severe 
valve regurgitation at diagnosis could explain the stable mortality despite the increase in the mean age of patients over time.
Keywords. epidemiology; etiology; infective endocarditis; secular trends; outcome.
 
Though a relatively rare disease (5–7 cases per 100 000 people/
year), infective endocarditis (IE) is an extremely serious condi-
tion due to its associated morbidity and high attributable mor-
tality [1].
The profile of IE has varied considerably since William 
Osler’s original description as a subacute or chronic pathol-
ogy of community-acquired infection in patients with previ-
ous rheumatic heart disease. Today, it is described as an acute 
acquired infection that is often health care related, occurring in 
elderly patients with degenerative heart disease, prostheses, or 
endovascular devices [2, 3]. However, epidemiological findings 
have not been uniform [4]. Regarding etiology, for example, 
while some studies have found no increase in the trend for a 
given pathogen [5], other authors have described a rise in 
coagulase-negative staphylococci (CoNS), enterococci [6], and 
Staphylococcus aureus [2, 4, 7].
Descriptive data about IE and knowledge of the changing 
spectrum of these local variations would be helpful for deter-
mining the impact of the disease and for optimizing its man-
agement. In this study, we aimed to identify and analyze secular 
trends in the clinical, etiological, treatment, and outcome char-




The study involved retrospective analysis of prospectively col-
lected data from all episodes of definite or possible IE in patients 
hospitalized over 20  years (between January 1, 1996, and 
December 31, 2015). Bellvitge University Hospital is a teach-
ing hospital with 700 beds in southern Barcelona in Catalonia, 
Spain. The institution has about 35  000 admissions per year, 
distributed in medical and surgical units, with 60 intensive care 
beds available. It is a referral center for adult patients from a 
M A J O R  A R T I C L E
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the work 
is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofy183
Received 4 April 2018; editorial decision 16 July 2018; accepted 25 July 2018.
aEqual contribution
Correspondence: G. Cuervo, MD, PhD, Department of Infectious Diseases, Hospital 
Universitari de Bellvitge, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain 
(guillermo.cuervo@bellvitgehospital.cat).
2 • OFID • Cuervo et al
population of more than 2 million inhabitants and covers multi-
ple specialties, including cardiac surgery. Patients with endocar-
ditis are usually transferred to our hospital in complicated cases 
and/or those requiring surgery.
The following data were collected from medical reports 
using a standardized protocol: demographic characteristics, 
comorbidities and predisposing factors, clinical characteris-
tics, microbiological data, antibiotic treatments administered, 
surgeries performed, and clinical outcomes. We included only 
episodes of possible or definite left-side valve IE (mitral and/
or aortic involvement). Those episodes with device-related 
infections (pacemaker and implantable defibrillators) and those 
with isolated right-side valve IE (as well as episodes occurring 
in intravenous drug users) were excluded from the study. Five 
4-year periods were arbitrarily defined: 1996–1999 (P1), 2000–
2003 (P2), 2004–2007 (P3), 2008–2011 (P4), and 2012–2015 
(P5). Trend analyses were performed along these 5 periods to 
identify the main epidemiological, etiological, and therapeutic 
aspects, as well as the clinical outcomes, associated with IE in 
this region.
Definitions
The Duke criteria [8], plus the modified variant of 2000 [9], 
were used to diagnose definite or possible IE. Acquisition was 
categorized as community-acquired or non-community-ac-
quired IE, the latter including episodes of nosocomial and 
health care–associated acquisition. Nosocomial IE was defined 
as that not present on admission, with symptom onset more 
than 48 hours after hospitalization and up to 6 months after dis-
charge [10]. Health care–associated IE was defined as IE present 
at hospital admission or within the first 48 hours of admission 
in a patient with a history of receiving intravenous therapy 
(including chemotherapy), transfer from a specialized nursing 
care facility, or hemodialysis within 90  days before the index 
admission [11]. Early and late prosthetic IE were defined as 
cases occurring within or after the first year of prosthetic valve 
placement, respectively [12]. Cerebral embolism was defined as 
those symptomatic episodes of ischemic stroke (either transient 
ischemic attacks or hemispheric infarctions) with radiological 
confirmation. All patients were followed up to 1  year, during 
which cure was defined as the absence of relapse or mortality 
and mortality was defined as the 1-year case fatality rate.
Microbiological Studies
Two to 4 sets of 2 blood samples of 8–10 mL each (BACTEC 
Plus Aerobic and Anaerobic [BD]) were taken 30 minutes 
apart if IE was suspected. The samples were then processed 
in either a BACTEC 9240 (until May 2010) or a BACTEC-FX 
(since May 2010; BD Microbiology Systems) with an incuba-
tion period of 5 days. Positive blood samples were subcultured 
onto chocolate agar. Identification and antibiotic susceptibil-
ity testing of gram-negative bacilli and Enterococcus spp. were 
performed using commercial panels of the MicroScan system 
(Beckman Coulter, Inc). Viridans group streptococci (VGS) and 
other gram-positive cocci, including CoNS and Haemophilus 
species, Aggregatibacter species, Cardiobacterium hominis, 
Eikenella corrodens, and Kingella species group bacteria, were 
identified using standard methods [13]. Antibiotic suscepti-
bility was tested by microdilution using commercial Sensititre 
panels (TREK Diagnostic Systems Ltd.) according to Clinical 
and Laboratory Standards Institute (CLSI) recommendations. 
The European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) and/or CLSI criteria were used to define 
susceptibility or resistance to antimicrobial agents [14, 15]. 
From November 2012 onwards, bacterial identification was 
performed by Matrix-Assisted Laser Desorption Ionisation 
(MALDI-Biotyper; Bruker Daltonics). For patients transferred 
from other hospitals after IE diagnosis, it is usual practice to 
request the shipment of the strains responsible for the infection 
to the microbiology laboratory to deepen studies (eg, determin-
ation of minimum inhibitory concentration, molecular studies 
and, in recent times, MALDI and sequencing studies). In add-
ition, the strains responsible for endocarditis are collected and 
stored for future studies.
Statistical Analysis
Continuous variables were compared using the Student t test 
or the Mann Whitney U test, as appropriate. Categorical data 
were compared using the Fisher exact test or the chi-square 
test. Trend analyses were carried out using Cochran-Mantel-
Haenszel tests for dichotomous variables and linear logistic 
regression for continuous data. Statistical significance was 
established at an α of .05, with all reported P values being 
2-tailed. Analyses were performed using SPSS Software, version 
15 (SPSS Inc., Chicago, IL).
Ethical Considerations
This observational study was carried out in accordance with the 
1964 Declaration of Helsinki and its later amendments. To pro-
tect privacy, the information of each patient was encrypted in an 
electronic database. Requests for informed consent were con-
sidered unnecessary by the Clinical Research Ethics Committee 
because no intervention was performed and no personally iden-
tifiable information was collected.
RESULTS
Patients’ Characteristics and Clinical Presentation
In total, 595 episodes of left-side valve IE were recorded in 564 
patients, with a definite diagnosis established in 473 (79.5%). 
Most cases affected the aortic valve or both the aortic and 
mitral valves (58.4%) and were community acquired (75.6%). 
Almost one-third of the episodes involved a prosthetic valve. 
The patients’ characteristics and the main clinical manifes-
tations are summarized by period in Table  1. Most patients 
(70%) were men, and the mean age (SD) was 64.1 (14.3) years. 
Of note, there was a significant increase in the mean age in 
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the last period (58.3 years in P1 vs 68 years in P5; P <  .001). 
Patients older than 70  years constituted more than one-half 
(51.9%) in the last period. There was a significant increase 
in patients older than 80 years from P1 (6.3%) to P5 (20.7%; 
P < .001). Most patients initially presented with fever (83.7%), 
and more than half had moderate to severe valvular regurgita-
tion. Neurological and immunological complications occurred 
in approximately 15.1% and 10.8% of patients, respectively. 
The median of symptom duration before diagnosis showed a 
nonsignificant decreasing trend (5.3 weeks in P1 vs 3.5 weeks 
in P5; P = .102).
Acquisition Site and Microbiology
Details of the acquisition site and causative agent are 
shown by period in Table  2. There was a trend toward an 
increase in prosthetic valve IE (25.3% in P1 to 36.3% in P5; 
P  =  .198), particularly with biological valves (30% in P1 to 
67.3% in P5; P <  .001). Despite this, there was no increase in 
non-community-acquired IE.
The temporal evolution by period for the different etiologies 
is shown in Figure  1. Overall, VGS were the most commonly 
isolated pathogens, followed by Staphylococcus aureus, CoNS, 
Enterococcus spp., and Streptococcus gallolyticus. Although the 
proportions remained stable over the 5 periods without any sta-
tistically significant upward or downward trend, IE caused by 
Enterococcus spp. and Streptococcus gallolyticus showed a slight 
increase in the last 2 study periods. In addition, CoNS were more 
frequent in early (38.5%) than in late (15.7%) prosthetic valve 
IE (P < .001). The etiology of late valve IE was similar to that of 
native IE, albeit with fewer cases due to VGS (Figures 2 and 3).
Outcomes
Data concerning valve surgery, clinical evolution, and the 
1-year case fatality rate are shown by period in Table 2. Valve 
surgery was required in 31.6% of patients during the follow-up 
period, of which 20% required urgent surgery. Surgery was 
also indicated, but not performed, in 8.2% of the remaining 
episodes. Overall, there was a significant reduction in surgical 














Male sex 417 (70.1) 57 (72.2) 80 (70.8) 99 (68.3) 94 (76.4) 87 (64.4) NS
Mean age, y
 Age (SD) 64.1 (14.3) 58.3 (14.13) 60.7 (13.46) 64.6 (13.76) 66 (15.28) 68 (13.18) <.001
 ≥70 244 (41) 12 (15.2) 32 (28.3) 66 (45.5) 64 (52) 70 (51.9) <.001
 ≥80 72 (12.1) 5 (6.3) 6 (5.3) 13 (9) 20 (16.3) 28 (20.7) <.001
Symptoms
 Fever 498 (83.7) 67 (84.8) 91 (80.5) 121 (83.4) 103 (83.7) 116 (85.9) NS
 Median duration of symptoms 
(IQR), wk
4.4 (0.7–8.1) 5.3 (2.7–7.9) 4.3 (1.1–7.5) 4.9 (0.4–9.4) 4.2 (0–8.5) 3.5 (0.4–6.7) .102
 Moderate–severe valvular 
regurgitation
357 (60) 60 (75.9) 75 (66.4) 84 (57.9) 67 (54.5) 71 (52.6) <.001
 Cardiac failure 232 (39) 35 (44.3) 51 (45.1) 51 (35.2) 38 (30.9) 57 (42.2) NS
Vascular phenomena 226 (38) 34 (43) 50 (44.2) 60 (41.4) 45 (36.6) 37 (27.4) .005
 Major arterial embolism 148 (24.9) 15 (19) 34 (30.1) 44 (30.3) 26 (21.1) 29 (21.5) NS
  Cerebral embolism 90 (15.1) 6 (7.6) 18 (15.9) 30 (20.7) 21 (17.1) 15 (11.1) NS
  Splenic embolism 32 (5.4) 4 (5.1) 10 (8.9) 8 (5.5) 4 (3.3) 6 (4.4) NS
  Renal embolism 11 (1.9) 2 (2.5) 4 (3.5) 4 (2.8) 0 1 (0.7) NS
  Coronary embolism 4 (0.7) 0 0 0 0 4 (3) –
  Other embolism 11 (1.9) 3 (3.8) 2 (1.8) 2 (1.4) 1 (0.8) 3 (2.2) NS
 Conjunctival hemorrhage 42 (7.1) 3 (3.8) 9 (8) 15 (10.3) 8 (6.5) 7 (5.2) NS
 Janeway lesions 36 (6.1) 7 (8.9) 5 (4.4) 16 (11) 6 (4.9) 2 (1.5) .037
 Mycotic aneurism 21 (3.5) 3 (3.8) 8 (7.1) 2 (1.4) 6 (4.9) 2 (1.5) NS
Immunologic phenomena 64 (10.8) 12 (15.2) 22 (19.5) 12 (8.3) 10 (8.1) 8 (6) .001
 Roth spots 22 (3.7) 8 (10.1) 5 (4.4) 3 (2.1) 3 (2.4) 3 (2.2) .011
 Osler nodes and cutaneous 
vasculitis
26 (4.4) 4 (5.1) 10 (8.8) 6 (4.1) 6 (4.9) 0 NS
 Reactive arthritis 24 (4) 1 (1.3) 7 (6.2) 10 (6.9) 2 (1.6) 4 (3) NS
 Glomerulonephritis 10 (1.7) 0 2 (1.8) 1 (0.7) 3 (2.4) 4 (3) NS
 Valvular abscess 79 (13.3) 17 (21.5) 11 (9.7) 19 (13.1) 16 (13) 16 (11.9) NS
 Septic arthritis and 
spondylodiscitis
56 (9.4) 10 (12.7) 12 (10.6) 13 (9) 6 (4.9) 15 (11.1) NS
 Splenomegaly 22 (3.7) 2 (2.5) 8 (7.1) 8 (5,5) 1 (0.8) 3 (2.2) NS
Periods: P1: January 1996–December 1999; P2: January 2000–December 2003; P3: January 2004–December 2007; P4: January 2008–December 2011; P5: January 2012–December 2015.
Abbreviations: IQR, interquartile range; NS, not significant.























Figure 1. Trends of causative pathogens. Abbreviations: CoNS, coagulase-negative staphylococci; VGS, viridans group streptococci.














Non-community-acquired 145 (24.4) 18 (22.8) 36 (31.9) 31 (21.4) 31 (25.2) 29 (21.5) NS
Affected valvea
 Aortic 277 (46.6) 36 (45.6) 47 (41.6) 68 (46.8) 62 (50.4) 64 (47.4) NS
 Mitral 241 (40.5) 32 (40.5) 56 (49.6) 60 (41.4) 42 (34.1) 51 (37.7) NS
 Aortic–mitral 70 (11.8) 10 (12.7) 9 (8) 15 (10.3) 19 (15.4) 17 (12.6) NS
Native valve IE 409 (68.7) 59 (74.7) 79 (69.9) 94 (64.8) 91 (74) 86 (63.7) NS
Prosthetic valve IE 186 (31.3) 20 (25.3) 34 (30.1) 51 (35.2) 32 (26) 49 (36.3) NS
 Mechanicalb 100 (53.7) 13 (65) 25 (73.5) 36 (70.6) 10 (31.2) 16 (32.7) <.001
 Biologicalb 84 (45.2) 6 (30) 9 (26.5) 14 (27.5) 22 (68.8) 33 (67.3) <.001
 Earlyb 52 (28) 8 (40) 8 (23.5) 11 (21.6) 7 (21.9) 18 (36.7) NS
 Lateb 134 (72) 12 (60) 26 (76.5) 40 (78.4) 25 (78.1) 31 (63.2) NS
Etiology
 Viridans group 
streptococci
147 (24.7) 23 (29.1) 22 (19.5) 40 (27.6) 29 (23.6) 33 (24.4) .05
 S. aureus 110 (18.5) 10 (12.7) 22 (19.5) 27 (18.6) 26 (21.1) 25 (18.5) NS
 Coagulase-negative 
staphylococci
84 (14.1) 12 (15.2) 15 (13.3) 16 (11) 15 (12.2) 26 (19.3) NS
 Enterococcus spp. 83 (13.9) 11 (13.9) 13 (11.5) 13 (9) 25 (20.3) 21 (15.6) .186
 S. gallolyticus 65 (10.9) 4 (5.1) 12 (10.6) 17 (11.7) 15 (12.2) 17 (12.6) .124
Indication for surgery 237 (39.8) 39 (49.4) 56 (49.6) 48 (33.1) 39 (31.7) 55 (40.7) .036
 Surgery performed 188 (31.6) 34 (43) 47 (41.6) 35 (24.1) 32 (26) 40 (29.6) .006
Cure 435 (73.1) 46 (58.2) 81 (71.7) 113 (77.9) 94 (76.4) 101 (74.8) .02
Global mortality 142 (23.9) 30 (38) 30 (26.5) 30 (20.7) 25 (20.3) 27 (20) .004
Periods: P1: January 1996–December 1999; P2: January 2000–December 2003; P3: January 2004–December 2007; P4: January 2008–December 2011; P5: January 2012–December 2015.
Abbreviations: NS, not significant; IE, infective endocarditis.
aMural IE cases not reflected. 
bThe percentages refer to the total of prosthetic valve endocarditis. Data about the type of prosthetic valve was missing in 2 cases.

















VGS Enterococcus spp. S. gallolyticusS. aureus CoNSHACEK group OtherFungalaUnknown
Figure 2. Etiology of native vs prosthetic valve infectious endocarditis. Bars indicate the frequency of each etiology in the whole study period. Dark gray: prosthetic; light 
gray: native. Significative differences are indicated in the figure. aThree cases caused by Candida spp. and 2 cases caused by Aspergillus spp. Abbreviations: CoNS, coag-
ulase-negative staphylococci; HACEK group bacteria, Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; 



















VGS Enterococcus spp. S. gallolyticusS. aureus CoNSHACEK group OtherFungal aUnknown
Figure  3. Etiology of early vs late prosthetic valve infectious endocarditis. Bars indicate the frequency of each etiology in the whole study period. Dark gray: early; 
light gray: late. Significative differences are indicated in the figure. Abbreviations: CoNS, coagulase-negative staphylococci; HACEK group bacteria, Haemophilus species, 
Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; VGS, viridans group streptococci . 
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interventions during the study period (43% in P1 to 29.6% in 
P5; P = .006).
The overall mortality of the cohort was 23.9%. It was highest 
in P1 (38%) but remained stable throughout the last 4 periods, 
reaching 20% in P5 (P = .004). Mortality was significantly higher 
for non-community-acquired IE (37.2% vs 19.6%; P = .001) and 
prosthetic valve IE (29% vs 21.5% in native valve IE; P = .046), 
with no difference between early and late prosthetic valve IE. 
Episodes with a clear indication for cardiac surgery, but in which 
surgery was not performed, were associated with significantly 
higher mortality (75.5% vs 20.2%; P  <  .001). Mortality rates 
by pathogen are shown in Supplementary Figure 1. Compared 
with IE caused by VGS, mortality was significantly higher for IE 
caused by S. aureus, methicillin-resistant S. aureus, and CoNS 
(a detailed description of patients with IE caused by CoNS who 
died is provided as a footnote in Supplementary Figure 1).
DISCUSSION
In the present study, we analyzed the details of 595 left-side 
valve IE episodes over a period of 20 years. During that time, 
we observed a shift in patient characteristics, with an increase 
in older patients that is consistent with other studies [6, 16, 17]. 
Given the aging population worldwide [18], the relative con-
tribution of infectious diseases is bound to increase in older 
patients [19]. In the case of IE, however, this epidemiological 
variation could be related to a change in the underlying heart 
pathology, with rheumatic heart disease increasingly being 
replaced by degenerative lesions and mitral valve prolapse 
[5, 16, 20], which are usually observed in older people. The 
increased mean age could explain the increase in IE among 
biological prosthetic valves in our series. Unlike other cohorts, 
however, there was no increase in prosthetic valve, nosocomial, 
or health care–associated IE in our study [5, 17, 21, 22]. This 
may result from our decision to exclude cardiac device–related 
IE [23].
Several studies have reported the emergence of S. aureus as a 
predominant etiology of IE, with a concurrent decrease in the 
dominance of VGS [4, 7]. In contrast to this pattern, a popula-
tion-based Spanish study noted that there had been a decline in 
the proportion of S. aureus over recent years [6]. In our setting, 
despite a nonsignificant decrease throughout the study period, 
the main etiology remained VGS with a stable percentage of 
S. aureus. This is in line with the findings of a population-based 
study in Olmsted County, Minnesota [5], and a recent review of 
IE epidemiology in Europe [24]. We detected a slight increase 
in the last 2 periods (without a statistically significant upward 
trend along the study period) of IE caused by Enterococcus spp. 
and S. gallolyticus, which are pathogens associated with urologi-
cal manipulations, colon cancer, and polyps [25–29], and which 
is therefore clearly related to an aging population [30].
Clinically, over the 5 periods evaluated in our cohort, we 
observed a decrease in the duration of symptoms before IE was 
diagnosed. Although this reduction did not reach statistical sig-
nificance, it could explain the significant reduction in vascular 
and immunological phenomena. This change in clinical pres-
entation has been reported previously [2, 4]. We also observed 
a progressive and significant reduction in cardiac surgery (per-
formed or indicated), which paralleled the significant reduction 
in severe valve dysfunction at the time of diagnosis. Conversely, 
other Western series have described increases in the indications 
for surgery with more severe and complicated case presenta-
tions [2, 4].
Finally, we found an initial decrease in mortality after the 
first period, though this remained stable at around 20% in 
the latter 4 periods. Again, this is consistent with most data 
published in the last decade, which have indicated that there 
have been few changes in mortality [24, 31]. Notwithstanding, 
a recent American cohort spanning a similar study period to 
ours (1998–2013) [17] showed that there were decreases in the 
90-day age- and comorbidity-adjusted mortality rates. Of note, 
it is possible that the use of new and more sensitive diagnostic 
tools could have helped to improve the detection of endocar-
ditis and its complications, and, consequently, episodes in the 
last periods may have been diagnosed in early stages. This stage 
migration phenomenon could partly explain the reductions 
observed in surgical interventions and in overall mortality in 
our cohort.
However, despite a large sample size and the long period 
spanned, there were 2 important limitations of our study. First, 
the fact that the information came from a single center means 
that caution is required when extrapolating the data. Second, 
our hospital is a referral center, which may bias our data toward 
more severe cases. On the other hand, although the patterns of 
referral did not formally change along the study period, it can-
not be ruled out that transfers of care from the referring hospi-
tals could have been optimized during the 20-year study period 
(for patients with more aggressive or advanced disease), which 
may explain the high mortality documented in the first period.
In conclusion, we found an increase in the proportion of 
elderly patients with IE in daily clinical practice but failed to 
identify any significant trends in etiology. The lower frequency 
of moderate to severe valve regurgitation at diagnosis could 
explain the stable mortality in spite of an increasing mean age 
during the study period.
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